The outlook revision reflects Moody’s Investors Service’s expectation that MedStar’s operations will remain pressured over the coming years.
Moody’s also affirmed the “A2” rating on MedStar’s bonds. The rating affirmation is based on numerous factors, including MedStar’s diversified clinical delivery network, strengthening market position and consistently profitable operations.
More articles on healthcare finance:
New England Baptist inks bundle deal for GE employees’ joint replacements
Medical device company Lensar files for bankruptcy
AMGA sends CMS’ Andy Slavitt MACRA recommendations: 6 things to know
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
